Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

Similar articles for PubMed (Select 19279441)

1.

Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.

Aldrovandi GM, Lindsey JC, Jacobson DL, Zadzilka A, Sheeran E, Moye J, Borum P, Meyer WA 3rd, Hardin DS, Mulligan K; Pediatric AIDS Clinical Trials Group P1045 team.

AIDS. 2009 Mar 27;23(6):661-72. doi: 10.1097/QAD.0b013e3283269dfb.

2.

Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors.

Melvin AJ, Lennon S, Mohan KM, Purnell JQ.

AIDS Res Hum Retroviruses. 2001 Aug 10;17(12):1117-23.

PMID:
11522181
3.

Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy.

Chantry CJ, Hughes MD, Alvero C, Cervia JS, Meyer WA 3rd, Hodge J, Borum P, Moye J Jr; PACTG 1010 Team.

Pediatrics. 2008 Jul;122(1):e129-38. doi: 10.1542/peds.2007-2467. Epub 2008 Jun 2.

4.

Obesity and dyslipidemia in behaviorally HIV-infected young women: Adolescent Trials Network study 021.

Mulligan K, Harris DR, Monte D, Stoszek S, Emmanuel P, Hardin DS, Kapogiannis BG, Worrell C, Meyer WA 3rd, Sleasman J, Wilson CM, Aldrovandi GM; Adolescent Trials Network 021 Protocol Team.

Clin Infect Dis. 2010 Jan 1;50(1):106-14. doi: 10.1086/648728.

5.

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA.

AIDS. 1998 May 7;12(7):F51-8.

PMID:
9619798
6.

Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children.

Bitnun A, Sochett E, Babyn P, Holowka S, Stephens D, Read S, King SM.

AIDS. 2003 Jun 13;17(9):1319-27.

PMID:
12799553
7.

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T.

Pediatrics. 2002 Nov;110(5):e56.

PMID:
12415062
8.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
9.

Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study.

Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang JM, Gastaut JA, Touraine JL.

AIDS. 2000 Jan 7;14(1):37-49.

PMID:
10714566
10.

The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children.

Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL.

Pediatrics. 2001 May;107(5):E77.

PMID:
11331727
11.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
12.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
14.

Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome.

Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL, Eckel RH.

AIDS. 2001 Oct 19;15(15):1993-2000.

PMID:
11600828
15.

Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use.

Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S.

J Clin Endocrinol Metab. 2000 Jan;85(1):35-41.

PMID:
10634360
16.

Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.

Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, Gatell JM, Cahn P, Chaves R.

AIDS. 2008 Nov 12;22(17):2313-21. doi: 10.1097/QAD.0b013e328315a7a5.

PMID:
18981770
17.

Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort.

El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, Grunfeld C, Raghavan SS.

HIV Med. 2005 Mar;6(2):114-21.

PMID:
15807717
18.

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.

Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, Doong N, French M, Smith D, Cooper DA; PIILR Study Group.

AIDS. 2001 Sep 28;15(14):1811-22.

PMID:
11579243
19.

Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.

Arpadi S, Shiau S, Strehlau R, Martens L, Patel F, Coovadia A, Abrams EJ, Kuhn L.

Arch Dis Child. 2013 Apr;98(4):258-64. doi: 10.1136/archdischild-2012-302633. Epub 2012 Dec 5.

PMID:
23220209
20.

Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients.

Walli R, Herfort O, Michl GM, Demant T, J├Ąger H, Dieterle C, Bogner JR, Landgraf R, Goebel FD.

AIDS. 1998 Oct 22;12(15):F167-73.

PMID:
9814858
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk